Clinical proteomics: The promises and challenges of mass spectrometry-based biomarker discovery

Clinical Advances in Hematology and Oncology

Volumn 4, Issue 7, 2006, Pages 541-549

  deVera, Imelda E ^a   Katz, Jonathan E ^a,b   Agus, David B ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Mass Spectometry Group

Author keywords

Mass spectrometry; Plasma; Profiling; Proteomics; Serum

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; BIOLOGICAL MARKER; FIBRINOGEN; HAPTOGLOBIN; IMMUNOGLOBULIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN; THROMBIN; TRANSFERRIN;

ANTIBODY DETECTION; BIOINFORMATICS; BLOOD ANALYSIS; CHEMOLUMINESCENCE; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METHODOLOGY; PRACTICE GUIDELINE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN MODIFICATION; PROTEIN PROCESSING; PROTEIN PURIFICATION; PROTEOMICS; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY;

BIOLOGICAL MARKERS; HUMAN GENOME PROJECT; HUMANS; MASS SPECTROMETRY; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 33747400963     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Kavallaris M, Marshall GM. Proteomics and disease: opportunities and challenges. Med J Aust. 2005;182:575-579.
2. Petricoin E, Wulfkuhle J, Espina V, Liona LA. Clinical proteomics: revolutionizing disease detection and patient tailoring therapy. J Proteome Res. 2004;3:209-217.
3. Katz JE, Mallick P, Agus DB. A perspective on protein profiling of blood. BJU Int. 2005;96:477-482.
4. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002;1:845-867.
5. Barrett J, Brophy PM, Hamilton JV. Analysing proteomic data. Int J Parasitol. 2005;35:543-553.
6. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002;359:572-577.
7. Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 2002;62:3609-3614.
8. Li J, Zhang Z, Rosenzweig J, Wang YY, Chats DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem. 2002;48:1296-1304.
9. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics. 2004;3:367-378.
10. Baggerly KA, Morris JS, Coombes KR. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics. 2004;20:777-785.
11. Liotta LA, Lowenthal M, Mehta A, et al. Importance of communication between producers and consumers of publicly available experimental data. J Natl Cancer Inst. 2005;97:310-314.
12. Misek DE, Kuick R, Wang H, et al. A wide range of protein isoforms in serum and plasma uncovered by a quantitative intact protein analysis system. Proteomics. 2005;5:3343-3352.
13. Banks RE, Stanley AJ, Cairns DA, et al. Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem. 2005;51:1637-1649.
14. Tammen H, Schulte I, Hess R, Menzel C, Kellmann M, Schutz-Knappe P. Prerequisites for peptidomic analysis of blood samples: I. Evaluation of blood specimen qualities and determination of technical performance characteristics. Comb Chem High Throughput Screen. 2005;8:725-733.
15. Chromy BA, Gonzales AD, Perkins J, et al. Proteomic analysis of human serum by two-dimensional differential gel electrophoresis after depletion of high-abundant proteins. J Proteome Res. 2004;3:1120-1127.
16. Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD. Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics. 2003;2:1096-1103.
17. Hulmes JD, Bethea D, Ho K, et al. An Investigation of Plasma Collection, Stabilization, and Storage Procedures for Proteomic Analysis of Clinical Samples. Clin Proteomics J. 2004;1:17-32.
18. Vitzthum F, Behrens F, Anderson NL, Shaw JH. Proteomics: from basic research to diagnostic application: a review of requirements & needs. J Proteome Res. 2005;4:1086-1097.
19. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer. 2004;4:309-314.
20. Pieper R, Su Q, Gatlin CL, Huang ST, Anderson NL, Steiner S. Multicomponent immunoaffinity subtraction chromatography: an innovative step towards a comprehensive survey of the human plasma proteome. Proteomics. 2003;3:422-432.
21. Fasano M, Curry S, Terreno E, et al. The extraordinary ligand binding properties of human serum albumin. IUBMB Life. 2005;57:787-796.
22. Zhou M, Lucas DA, Chan KC, et al. An investigation into the human serum "interactome". Electrophoresis. 2004;25:1289-1298.
23. Liotta LA, Petricoin EF. Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest. 2006;116:26-30.
24. Lowenthal MS, Mehta AI, Frogale K, et al. Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem. 2005;51:1933-1945.
25. Zolotarjova N, Martosella J, Nicol G, Bailey J, Boyes BE, Barrett WC. Differences among techniques for high-abundant protein depletion. Proteomics. 2005;5:3304-3313.
26. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol. 1999;17:994-999.
27. Li J, Steen H, Gygi SP. Protein profiling with cleavable isotope-coded affinity tag (cICAT) reagents: the yeast salinity stress response. Mol Cell Proteomics. 2003;2:1198-1204.
28. Patton WF, Schulenberg B, Steinberg TH. Two-dimensional gel electrophoresis; better than a poke in the ICAT? Curr Opin Biotechnol. 2002;13:321-328.
29. Haynes PA, Yates JR, 3rd. Proteome profiling-pitfalls and progress. Yeast. 2000;17:81-87.
30. Kaji H, Saito H, Yamauchi Y, et al. Lectin affinity capture, isotope-coded tagging and mass spectrometry to identify N-linked glycoproteins. Nat Biotechnol. 2003;21:667-672.
31. Hagglund P, Bunkenborg J, Elortza F, Jensen ON, Roepstorff P. A new strategy for identification of N-glycosylated proteins and unambiguous assignment of their glycosylation sites using HILIC enrichment and partial deglycosylation. J Proteome Res. 2004;3:556-566.
32. Zhang H, Li XJ, Martin DB, Aebersold R. Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol. 2003;21:660-666.
33. Alvarez-Manilla G, Atwood J 3rd, Guo Y, Warren NL, Orlando R, Pierce M. Tools for glycoproteomic analysis: size exclusion chromatography facilitates identification of tryptic glycopeptides with N-linked glycosylation sites. J Proteome Res. 2006;5:701-708.
34. Orntoft TF, Vestergaard EM. Clinical aspects of altered glycosylation of glycoproteins in cancer. Electrophoresis. 1999;20:362-371.
35. Matrisian LM, Sledge GW Jr, Mohla S. Extracellular proteolysis and cancer: meeting summary and future directions. Cancer Res. 2003;63:6105-6109.
36. Silveira PF, Gil J, Casis L, Irazusta J. Peptide metabolism and the control of body fluid homeostasis. Curr Med Chem Cardiovasc Hematol Agents. 2004;2:219-238.
37. Lopez-Otin C, Overall CM. Protease degradomics: a new challenge for proteomics. Nat Rev Mol Cell Biol. 2002;3:509-519.
38. Villanueva J, Shaffer DR, Philip J, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest. 2006;116:271-284.
39. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005;5:845-856.
40. Roboz J. Mass spectrometry in diagnostic oncoproteomics. Cancer Invest. 2005;23:465-478.
41. Varma S, Simon R. Bias in error estimation when using cross-validation for model selection. BMC Bioinformatics. 2006;7:91.
42. Bast RC Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883-887.
43. Luscombe NM, Greenbaum D, Gerstein M. What is bioinformatics? A proposed definition and overview of the field. Methods Inf Med. 2001;40:346-358.
44. Frazier DM, Millington DS, McCandless SE, et al. The tandem mass spectrometry newborn screening experience in North Carolina: 1997-2005. J Inherit Metab Dis. 2006;29:76-85.
45. Carr S, Aebersold R, Baldwin M, Burlingame A, Clauser K, Nesvizhskii A. The need for guidelines in publication of peptide and protein identification data: Working Group on Publication Guidelines for Peptide and Protein Identification Data. Mol Cell Proteomics. 2004;3:531-533.
46. Keller A, Nesvizhskii AI, Kolker E, Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem. 2002;74:5383-5392.
47. Bradshaw RA, Burlingame AL. From proteins to proteomic. IUBMB Life. 2005;57:267-272.
48. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350:2239-2246.
49. Ransohoff DF, McNaughton Collins M, Fowler FJ. Why is prostate cancer screening so common when the evidence is so uncertain? A system without negative feedback. Am J Med. 2002;113:663-667.